Grape King Bio Ltd (TPE:1707)

Taiwan · Delayed Price · Currency is TWD

92.50

+0.60 (0.65%)

Jul 16, 2026, 1:30 PM CST

-25.10% (1Y)

Market Cap	13.61B -29.6%
Revenue (ttm)	10.28B -7.1%
Net Income	1.19B -15.2%
EPS	7.94 -15.4%
Shares Out	148.14M
PE Ratio	11.57
Forward PE	n/a
Dividend	6.00 (6.53%)
Ex-Dividend Date	Jun 17, 2026

Volume	322,664
Open	92.00
Previous Close	91.90
Day's Range	91.80 - 93.20
52-Week Range	90.00 - 138.00
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes. It also offers functional ingredients for intestinal care, immunity regulatio... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1969

Employees 501

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 1707

Full Company Profile

Financial Performance

In 2025, Grape King Bio's revenue was 10.25 billion, a decrease of -8.14% compared to the previous year's 11.16 billion. Earnings were 1.22 billion, a decrease of -15.88%.

Financial Statements